结直肠癌患者肿瘤组织及血清ADAM10的表达

Abstract
Figure/Table
References (0)
Related Citation (12)

Download: PDF (2484 KB) HTML (1 KB)
Export: BibTeX | EndNote (RIS)

Abstract Objective: To detect the expression of ADAM10 in colorectal cancer tissue and serum, analyze the relationship between colorectal cancer occurrence, development, and clinical pathological characteristics. Methods: Samples of 59 colorectal cancer tissues, 30 colorectal polyps tissues and 30 health human of normal intestinal mucosa tissue were collected to detect the expressions of ADAM10 with immunohistochemistry SP. ADAM10 expression in serum of the above three groups was detected with double antibody sandwich ELISA method. Results: The expression level of ADAM10 in serum and tissue in the colorectal cancer patients was significantly higher than that in colorectal polyps groups and normal control groups (P<0.001). ADAM10 expression levels were elevated in serum and tissue of the colorectal cancer patients with the increase of tumor Duke stage. The expression level of ADAM10 in serum and tissue of the colorectal cancer patients was no relationship with the sex, age, the location of the tumor, tumor size, histological type (P>0.05), and was correlated with the tumor differentiation, lymphoid node diversion, distant metastasize, Duke stage (P<0.01). Conclusion: Colorectal cancer patients has higher expression of ADAM10 in cancer tissue and serum, and related with clinical pathological characteristics of colorectal cancer. It has a certain clinical value in the diagnosis of colorectal cancer.

Key words： colorectal neoplasms athological analysis adisintegrin and metalloproteinase 10

Received: 22 April 2015

	Service
	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors
	ZHENG Jia
	SHENG Xiancang.

URL:

https://xb.wmu.edu.cn/EN/ OR https://xb.wmu.edu.cn/EN/Y2016/V46/I3/190

[1] GIBB D R, EISHIKH M, KANG D J, et a1. ADAM10 is essential for Notch2—dependent marginal zone B cell development and CD23 cleavage in vivo[J]. J Exp Med, 2010, 207(3): 623-635.
[2] MOCHIZUKI S, OKADA Y. ADAMs in cancer cell proliferation and progression[J]. Cancer Sci, 2007, 98(5): 621-628.
[3] ARIMA T, ENOKIDA H, KUBO H, et a1. Nuclear translocation of ADAM-10 contributes to the pathogenesis and progression of human prostate cancer[J]. Cancer Sci, 2007, 98 (11): 1720-1726.
[4] LEE S B, SCHRAMME A, DOBERSTEIN K, et a1. ADAMl0 is upregulated in melanoma metastasis compared with primary melanoma[J]. J Invest Dermatol, 2010, 130(3): 763-773.
[5] GAVERT N, SHEFFER M, RAVEH S, et a1. Expression of L1-CAM and ADAMl0 in human colon cancer cells induces metastasis[J]. Cancer Res, 2007, 67(16): 7703-7712．
[6] KO S Y, LIN S C, WONG Y K, et a1. Increase of disintergin metalloprotease10 (ADAMl0) expression in oral squamous cell carcinoma[J]. Cancer Lett, 2007, 245(1-2): 33-43.
[7] WU E, CROUCHER P I, MCKIE N. Expression of members of the novel membrane linked metalloproteinase family ADAM in cells derived from range of haematological malignancies[J]. Biochem Biophys Res Commun, 1997, 235(2): 437-442.
[8] FREESE C, GARRATT A N, FAHRENHOLZ F, et al. The effects of alpha-secretase ADAM10 on the proteolysis of neuregulin-1[J]FEBS, 2009, 276(6): 1568-1580.
[9] KOHUTEK Z A, DIPIERRO C C, REDPATH G T, et al. ADAM-10-mediated N-cadherin cleavage is protein kinase C-alpha dependent and promotes glioblastoma cell migration [J]. J Neurosci, 2009, 29(14): 4605-4615.
[10] 关艳, 邝晓聪, 姚金光. ADAM10在舌癌中的表达及其意义[J]. 口腔医学研究, 2011, 27(11): 981-983.
[11] MOCHIZUKI S, OKADA Y. ADAMs in cancer cell proliferation and progression[J]. Cancer Sci, 2007, 98(5): 621-628.
[12] MURAI T, MIYAZAKI Y, NISHINAKAMURA H, et al. Engagement of CD44 promotes Rac activation and CD44 cleavage during tumor cell migration[J]. J Biol Chem, 2004, 279(6): 4541-4550.
[13] SCHULZ B, PRUESSMEYER J, MARETZKY T, et al. AD-AM10 regulates endothelial permeability and T-Cell transmigration by proteolysis of vascular endothelial cadherin[J]. Circ Res, 2008, 102(10): 1192-1201.
[14] FOGEL M, GUTWEIN P, MECHTERSHEIMER S, et al. L1 expression as a predictor of progression and survival in patients with uterine and ovarian carcinomas[J]. Lancet,2003, 362(9387): 869-875.